Who ChondroFiller is designed for

ChondroFiller is designed for a specific clinical picture: a localised patch of cartilage damage at Grade III or IV depth — meaning the cartilage has been lost through more than half its thickness, or down to the bone beneath — within an otherwise reasonably healthy knee. Defects of this kind are typically up to 3 cm² in size, though the manufacturer's clinical evidence report extends the indication to 6 cm² in suitable cases. They usually arise from a sports injury, a previous knee trauma, or focal mechanical wear on one part of the joint surface.

The treatment is not intended for generalised osteoarthritis, where cartilage has thinned across broad areas of the joint. Patients with bone-on-bone wear throughout the knee, or with advanced degenerative changes, are unlikely to be suitable candidates — and being clear about this distinction helps patients and clinicians alike reach the right decision quickly.

Age is not, in itself, a barrier for the injection pathway. Suitability is determined by the nature and extent of the defect, not a patient's years. Active individuals in their 30s, 40s, and beyond with a discrete lesion confirmed on imaging may all fall within the indicated group.

The essential first step is an MRI review. Scanning establishes defect size, depth, and the condition of the surrounding joint before any treatment decision is made. No clinical assessment can reliably confirm candidacy without it.

How the collagen scaffold works inside the knee

At the centre of a Grade III or IV lesion is essentially a crater in the joint surface — an area where cartilage has been lost and the underlying bone is exposed or poorly protected. Left unfilled, that gap creates abnormal load concentration and an environment that does not naturally favour repair.

ChondroFiller is a CE-marked Class III medical device composed of acellular Type I collagen — it contains no donor cells of any kind. Once injected under ultrasound guidance, the liquid collagen self-gels within minutes, conforming closely to the contour of the defect and providing an immediate three-dimensional matrix within the joint surface.

The scaffold then supports the body's own repair processes through a mechanism called acellular matrix-induced chondrogenesis. Progenitor cells — drawn from the surrounding synovium and the subchondral bone beneath the defect — migrate into the collagen framework, populate the matrix, and progressively differentiate into chondrocyte-like cells that begin building new tissue. The scaffold itself is gradually resorbed as that tissue matures; it is a temporary biological structure, not a permanent implant.

The repair tissue that forms tends toward a hyaline-like composition. This is a meaningful distinction from microfracture, a more established technique that stimulates the marrow but typically produces fibrocartilage — a stiffer, less resilient tissue that may deteriorate more quickly under load. Hyaline-like repair tissue more closely resembles native articular cartilage in its structural properties, though how well that translates into long-term function varies between individuals.

What happens at your appointment

The appointment follows a clear sequence that most patients find straightforward.

Before treatment day, an in-clinic assessment — or a review of MRI already in hand — confirms that the defect size and joint condition make the treatment appropriate. This stage exists to filter out cases where generalised wear across the joint would mean the procedure is unlikely to help. No one proceeds to injection without that step.

On the day itself, everything takes place in an outpatient clinic setting. There is no theatre admission, no general anaesthetic, and no incisions. The collagen gel is delivered through a fine needle under image guidance, filling the defect precisely. The full appointment — assessment, injection, and a brief post-procedure check — typically runs 30–45 minutes, and patients leave the same day.

In the first few days, mild discomfort and some localised swelling around the knee are a normal part of the early healing response. Most patients manage this comfortably with rest and standard analgesia, alongside the specific loading and activity advice given at the appointment.

Over the following one to two weeks, activity is kept reduced while the scaffold settles into place. For most patients, normal daily movement — walking, driving, desk-based work — resumes within that window. Return to sport is a separate, individually guided process that takes considerably longer; the joint is actively repairing, and load progression should follow clinical advice rather than any fixed timetable. Surgical cartilage repair pathways, by contrast, typically involve several months of structured rehabilitation before high-impact activity is permitted — a meaningful difference for patients weighing their options.

Outcomes and what the evidence shows

Three measures capture what the evidence currently shows: functional improvement, structural repair quality, and safety across a large treated population.

Functional scores. Across manufacturer-sponsored and independent studies, International Knee Documentation Committee (IKDC) scores improve by approximately 30 points at 12–36 months post-treatment — a shift that, in clinical terms, corresponds to a meaningful reduction in knee pain and a return to activities patients had been limiting or avoiding.

Structural repair on MRI. MOCART scores of 70–87 — a validated scale assessing cartilage fill, integration, and surface quality on MRI — indicate consistent, high-quality structural repair across reported cohorts. A 2025 study published via PMC (PMC12498443) adds independent corroboration: ChondroFiller-treated patients showed significantly better cartilage quality versus controls at follow-up arthroscopy, with median Outerbridge scores of 1.5 versus 3.0 (P=0.006) and ICRS scores of 1 versus 3 (P=0.002).

Safety across a large case series. More than 19,000 cases have been treated worldwide, with zero serious complications reported in published data. The reoperation rate of 3–8% compares favourably with rates of up to 41% reported for microfracture, reflecting a more stable repair environment rather than a surface dependent on fibrocartilage under load.

Reported symptom-relief success rates sit in the range of 70–85% at population level — a useful anchor, not a personal prediction. Large independent head-to-head randomised controlled trials remain limited, so these figures are best understood as the evidence base within which a clinical assessment determines what a specific defect size, joint condition, and activity goal make realistic.

Cost and how Lincolnshire patients access treatment

Practical access for patients in Lincolnshire involves two honest realities: ChondroFiller is not available on the NHS anywhere in the UK, and there is currently no publicly identifiable ChondroFiller provider operating locally in Lincolnshire.

Guide costs for the injection pathway start from approximately £2,800–£3,000 per treatment box at specialist centres, with most focal defects treated using a single box. These figures are indicative — the final cost depends on defect extent, the specific centre, and any additional diagnostics not bundled into the package. Always confirm exact pricing directly with the treating clinic at assessment.

For Lincolnshire patients, the established route is referral or self-referral to a specialist centre. London Cartilage Clinic at 66 Harley Street — where Professor Paul Y.F. Lee leads the programme — is the primary UK centre for the injection pathway. The journey is a practical consideration rather than a clinical obstacle; the appointment itself is a single outpatient visit.

A sensible starting point before travelling to London is a local assessment through Lincolnshire Knee, which is part of the MSK Doctors group and accepts patients without a GP referral. An initial consultation can confirm focal defect suitability, review existing MRI, or commission a fresh scan with onMRI™ cartilage analysis — meaning patients arrive at any London appointment with a clear clinical picture already in hand, rather than repeating that groundwork at extra cost.

On private health insurance: Bupa, Aviva, and WPA have been among the insurers where approval has been reported, billed under CCSD codes W3111 and W8500. Written pre-authorisation is mandatory before booking — coverage is not guaranteed and varies significantly by policy. Contact your insurer before committing to any appointment.

To start an assessment without a referral, visit lincolnshireknee.co.uk.

Is ChondroFiller the right choice for your knee

Pulling together what sections 1 through 5 establish, the decision rests on three structural prerequisites that go beyond defect size alone. Unaddressed malalignment — significant varus or valgus loading — and unstable ligament injuries are the conditions most likely to undermine any cartilage repair, including this one; placing a scaffold into a mechanically hostile joint is unlikely to produce the outcomes the evidence describes. Neither is a reason to rule out treatment permanently, but each needs to be assessed and, where possible, resolved first.

Patients who don't meet the focal-defect criteria — for instance those with broader joint-space involvement or inflammatory change — are not without options. Platelet-rich plasma (PRP) and biologics such as BMAC or microfragmented adipose tissue address different aspects of joint health and may be more appropriate for presentations that fall outside ChondroFiller's specific indication.

Self-diagnosis from symptoms is unreliable here. Pain and stiffness don't distinguish a 1 cm² Grade IV lesion from early generalised osteoarthritis, and the treatment pathway that follows each is different. MRI characterisation — including AI-assisted cartilage segmentation via onMRI™ if a fresh scan is needed — is what converts a promising option into a confirmed plan.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. Book an assessment at lincolnshireknee.co.uk.